Antimicrobial synergism in the therapy of experimental cerebral nocardiosis.
A mouse model of cerebral nocardiosis was used to determine the efficacy of synergistic antimicrobial combinations in reducing bacterial colony counts per gram of brain tissue. The combinations of imipenem-cefotaxime and imipenem-trimethoprim/sulphamethoxazole (TMP/SMP) were compared with each other and with each agent used alone. A saline treated control group was also included. At the completion of 72 h of therapy the combinations of imipenem-cefotaxime and imipenem-TMP/SMX were the most effective in reducing bacterial colony counts. These were statistically superior to cefotaxime and TMP/SMX used alone but not statistically superior to imipenem alone. TMP/SMX was not effective in this model and was inferior to all other antibiotic treatments.
Gombert
M E
ME
Department of Medicine, State University of New York, Health Science Center, Brooklyn 11203.
duBouchet
L
L
Aulicino
T M
TM
Berkowitz
L B
LB
D000818:Animals; D001927:Brain Diseases / Q000188:drug therapy* / Q000382:microbiology; D002439:Cefotaxime / Q000627:therapeutic use; D015169:Colony Count, Microbial; D004338:Drug Combinations / Q000627:therapeutic use; D004357:Drug Synergism; D004359:Drug Therapy, Combination / Q000627:therapeutic use*; D005260:Female; D015378:Imipenem / Q000627:therapeutic use; D051379:Mice; D008826:Microbial Sensitivity Tests; D009617:Nocardia Infections / Q000188:drug therapy* / Q000382:microbiology; D009616:Nocardia asteroides / Q000187:drug effects; D013420:Sulfamethoxazole / Q000627:therapeutic use; D014295:Trimethoprim / Q000627:therapeutic use; D015662:Trimethoprim, Sulfamethoxazole Drug Combination
D004338:Drug Combinations; D015378:Imipenem; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D014295:Trimethoprim; D013420:Sulfamethoxazole; D002439:Cefotaxime